More than two years after the World Health Organization (WHO) declared an end to the emergency phase of the Covid-19 pandemic ...

WHO noted that prequalified tests can now be prioritized in pooled procurement mechanisms, which help lower prices, stabilize ...

WHO said the decision builds on earlier emergency approvals and reflects the continued need for affordable, fast COVID-19 testing even after the pandemic’s emergency phase.

The response to the global COVID-19 pandemic by public health entities and the vaccine industry was unprecedented and highly successful (1, 2). The focus of the first-generation vaccines was on the ...

QuidelOrtho has launched the QuickVue Influenza + SARS Test for professional use. The test simultaneously detects and differentiates influenza A, influenza B, and SARS-CoV-2 antigens from a single ...

Azelastine also shows increase in mean time to SARS-CoV-2 infection, reduction in symptomatic infections. HealthDay News — Azelastine nasal spray is associated with a reduced risk for severe acute ...

The Institute of Biotechnology and Genetic Engineering, Chulalongkorn University, Bangkok 10330, Thailand National Center for Genetic Engineering and Biotechnology, National Science and Technology ...

In the intention-to-treat population, the incidence of polymerase chain reaction-confirmed SARS-CoV-2 infection was significantly lower in the azelastine group vs the placebo group. HealthDay News — ...

The polymerase chain reaction-confirmed SARS-CoV-2 infection rate was 2.2% with azelastine vs 6.7% with placebo. HealthDay News — Azelastine nasal spray is associated with a reduced risk for severe ...

Azelastine nasal spray is associated with a reduced risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. HealthDay News — Azelastine nasal spray is associated with a ...